YMAB
Y-Mabs Therapeutics Inc

660
Mkt Cap
$391.22M
Volume
760,675.00
52W High
$16.11
52W Low
$3.55
PE Ratio
-17.40
YMAB Fundamentals
Price
$8.61
Prev Close
$8.59
Open
$8.59
50D MA
$7.53
Beta
1.46
Avg. Volume
2.09M
EPS (Annual)
-$0.6692
P/B
4.47
Rev/Employee
$819,485.98
Loading...
Loading...
News
all
press releases
Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Zacks·3mo ago
News Placeholder
More News
News Placeholder
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of +74.07% and +5.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates
Keros Therapeutics (KROS) delivered earnings and revenue surprises of +33.33% and +135.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·4mo ago
News Placeholder
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know
YmAbs Therapeutics (YMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·5mo ago
News Placeholder
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
Zacks·7mo ago

Latest YMAB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.